The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.
The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...
Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...
The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.
The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...
Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...
The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate ...
Adding pembrolizumab to docetaxel does not appreciably affect efficacy outcomes among patients who received prior treatment for metastatic castration-resistant prostate cancer (mCRPC).
Vietnam Investment Review on MSN16h
Bayer Pharmaceuticals poised for landmark year"2025 is set to be a landmark year for Bayer Pharmaceuticals. We are bringing a number of groundbreaking products and our ...
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback